Ignyta to Debut Preclinical Data on RXDX-106 at the 2016 EORTC-NCI-AACR Annual Meeting
November 29 2016 - 5:45AM
Business Wire
Additional data highlighting Ignyta’s pipeline
of molecularly targeted oncology therapies, including entrectinib
and RXDX-105, will also be presented
Ignyta, Inc. (Nasdaq: RXDX), a biotechnology company
focused on precision medicine in oncology, today announced its
first disclosed preclinical data on RXDX-106—its potent, selective,
type II pseudo-irreversible inhibitor of TYRO3, AXL and MER (or
TAM) and c-MET—will be presented at the 2016 EORTC-NCI-AACR (ENA)
Molecular Targets and Cancer Therapeutics Symposium in Munich,
Germany, highlighting both the immuno-oncology and targeted
therapeutic activity of this novel agent. Additionally, the company
will present data on multiple compounds in clinical development
from its robust pipeline of molecularly targeted oncology
therapies, including entrectinib—an orally available, CNS-penetrant
tyrosine kinase inhibitor targeting tumors that harbor TRK,
ROS1 or ALK fusions—and RXDX-105—a VEGFR-sparing,
potent RET inhibitor.
“We are pleased to introduce preclinical data on RXDX-106 at ENA
alongside our promising clinical data for entrectinib and
RXDX-105,” said Jonathan Lim, M.D., Chairman and CEO of Ignyta.
“RXDX-106 is an intriguing, novel agent that may offer a dual
mechanism by potentiating the immune system, while also providing
selective activity against key molecular targets involved in both
primary oncogenesis and resistance.”
In the presented preclinical data on RXDX-106, researchers
demonstrated that the agent is a potent and selective inhibitor of
TAM and c-MET, and inhibited TAM-mediated and c-MET-mediated tumor
growth in vivo. Additionally, researchers demonstrated, via in
vitro and in vivo studies, that RXDX-106, as a single agent,
appears to release the molecular brakes on immune activation in
macrophages, NK cells, and T cells, resulting in the repolarization
of the immune response to elicit an anti-tumor effect. Furthermore,
emerging in vivo combination data suggest that RXDX-106 potentiates
the activity of anti-PD-1 and anti-CTLA-4 agents. These data
further support the continued evaluation of RXDX-106 in both a
preclinical and clinical setting (Abstract number 73, Poster number
P044; Abstract number 65, Poster number P036).
Also presented as part of this poster session were preclinical
data on RXDX-105 demonstrating significant anti-tumor activity in
models harboring RET fusions (Abstract number 85, Poster number
P056), as well as preclinical data on entrectinib showing potent
anti-tumor activity in multiple different tumor model systems
driven by NTRK1/2/3, ROS1 and ALK fusions, regardless of the fusion
partners or the tumor tissue of origin (Abstract number 78, Poster
number P049). Additional clinical data on RXDX-105 and entrectinib
will be presented later in the week at ENA.
About Ignyta, Inc.
Blazing a New Future for Patients with
Cancer™
At Ignyta, we work tirelessly on behalf of patients with cancer
to offer potentially life-saving, precisely targeted therapeutics
(Rx) guided by companion diagnostic (Dx) tests. Our integrated
Rx/Dx strategy allows us to enter uncharted territory, illuminating
the molecular drivers of cancer and quickly advancing treatments to
address them. This approach embraces even those patients with the
rarest cancers, who have the highest unmet need and who may
otherwise not have access to effective treatment options. With our
pipeline of potentially first-in-class and best-in-class precision
medicines, we are pursuing the ultimate goal of not just shrinking
tumors, but eradicating cancer relapse and recurrence in precisely
defined patient populations.
For more information, please visit: www.ignyta.com.
Forward-Looking Statements
This press release contains forward-looking statements
about Ignyta as that term is defined in Section 27A of
the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934. Statements in this press release that are not
purely historical are forward-looking statements. Such
forward-looking statements include, among other things, references
to preclinical data with respect to RXDX-105 and RXDX-106, the
implications of such preclinical data and the development of
Ignyta's product candidates. Actual results could differ from those
projected in any forward-looking statements due to numerous
factors. Such factors include, among others, the inherent
uncertainties associated with developing new products or
technologies and operating as a development stage company; Ignyta's
ability to develop, initiate or complete preclinical studies and
clinical trials for, obtain approvals for and commercialize any of
its product candidates; changes in Ignyta's plans to develop and
commercialize its product candidates; the potential for final
results of the ongoing clinical trials of RXDX-105 or other product
candidates, or any future clinical trials of RXDX-105 or other
product candidates, to differ from preliminary or expected results;
Ignyta's ability to raise any additional funding it will need to
continue to pursue its business and product development plans;
regulatory developments in the United States and foreign
countries; Ignyta's ability to obtain and maintain intellectual
property protection for its product candidates; the risk that
orphan drug exclusivity may not effectively protect a product from
competition and that such exclusivity may not be maintained; the
potential for the company to fail to maintain the CAP accreditation
and CLIA certification of its diagnostic laboratory; the loss of
key scientific or management personnel; competition in the industry
in which Ignyta operates; and market conditions. These
forward-looking statements are made as of the date of this press
release, and Ignyta assumes no obligation to update the
forward-looking statements, or to update the reasons why actual
results could differ from those projected in the forward-looking
statements. Investors should consult all of the information set
forth herein and should also refer to the risk factor disclosure
set forth in the reports and other documents the company files with
the SEC available at www.sec.gov, including without
limitation Ignyta's Annual Report on Form 10-K for the year
ended December 31, 2015 and subsequent Quarterly Reports
on Form 10-Q.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20161129005492/en/
Ignyta, Inc.Jacob Chacko, M.D.CFO858-255-5959jc@ignyta.com
Prometheus Biosciences (NASDAQ:RXDX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Prometheus Biosciences (NASDAQ:RXDX)
Historical Stock Chart
From Apr 2023 to Apr 2024